Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FMEE4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,831
Award facts
- Contract value 100% obligated
- $24,831.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $24,831.25 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Entyvio 300 mg vials. The delivery order, issued on January 7, 2026, with an ultimate completion date of January 8, 2026, was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This award represents a single delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide recurring pharmaceutical supplies to military healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award IDC under PPV-G GEN V with a ceiling value of $499,999,999 and completion date of December 31, 2036, structured across a 30-month base period and three 30-month option periods. The company supplies a comprehensive portfolio of pharmaceuticals and medical consumables to support Department of Defense healthcare operations globally, including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. As a critical pharmaceutical supplier within the federal military medical supply chain, DMS Pharmaceutical Group has demonstrated substantial performance capability through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, with no subcontractor relationships identified in its federal contracting activities.
Quick answers
Who was awarded contract SPE2DR26FMEE4?
SPE2DR26FMEE4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FMEE4 worth?
The government has obligated $24,831 on SPE2DR26FMEE4.
Is contract SPE2DR26FMEE4 an order under another contract?
Yes. SPE2DR26FMEE4 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEE4 competed?
The extent of competition for SPE2DR26FMEE4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award